Skip to main content
SpringerLink
Log in

Use of Antipsychotics in the Management of Schizophrenia during Pregnancy

  • Therapy in Practice
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The rapid development of pharmacotherapy has resulted in a growing clinical importance for the treatment of the increasing number of women with schizophrenia during pregnancy. An evolving database on reproductive health safety factors for women with schizophrenia has begun to be of assistance in optimising clinical benefits for women with childbearing potential.

Given the prevalence of antipsychotic use during pregnancy in women with schizophrenia, it is important for the clinician to have a prepared approach to the administration of these agents. In general, the use of psychotropic medication during pregnancy is indicated when risk to the fetus from exposure to this medication is outweighed by the risks of untreated psychiatric illness in the mother. The preponderance of evidence from registries to large health surveys indicate that treatment with antipsychotic medication confers either no or a small nonspecific risk for organ malformations.

According to the relevant literature published on the safety of antipsychotic medication during pregnancy, the findings are encouraging; however, the currently available data are very limited. Until there are more controlled prospective data on the impact of drugs on fetal and later development, the clinician will continue to work in a state of potential uncertainty, weighing partially estimated risks against managing individual clinical problems. The aim for the clinician should be to provide the best information available regarding the scope of possible risks associated with the treatment of schizophrenia during pregnancy. On the basis of the available data, generalisation is impossible and recommendations should be made on a drug-by-drug basis. The risks and benefits must always be carefully weighed for each patient on an individual basis. Only a woman who is well enough to acknowledge her pregnancy and her mental illness can effectively weigh the relative and partially unknown risks of treatment with antipsychotic medication against the highly probable risks of illness exacerbation if untreated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Stevens BC. Psychoses associated with childbirth: a demographic survey since the development of community care. Soc Sci Med 1971; 5: 527–9

    Article  PubMed  CAS  Google Scholar 

  2. Trixler M, Gáti Á, Tényi T. Risks associated with childbearing in schizophrenia. Acta Psychiatr Belg 1995; 95: 159–62

    PubMed  CAS  Google Scholar 

  3. Bratfos O, Haug JI. Puerperal mental disorders in manic-depressive females. Acta Psychiatr Scand 1966; 42: 285–8

    Article  PubMed  CAS  Google Scholar 

  4. Reich T, Winokur G. Postpartum psychoses in patients with manic-depressive disease. J Nerv Ment Dis 1970; 151: 60–4

    Article  PubMed  CAS  Google Scholar 

  5. McKenna K, Einarson A, Levinson A, et al. Significant changes in antipsychotic drug use during pregnancy. Vet Hum Toxicol 2004; 46: 44–6

    PubMed  Google Scholar 

  6. Reynolds R. The effects on the infant of psychotropic drugs used in pregnancy. In: Krauer B, Krauer F, Hytten FE, et al., editors. Drugs in pregnancy: maternal drug handling, fetal drug exposure. London: Academic Press, 1984: 131–50

    Google Scholar 

  7. Goldberg HL, Nissim R. Psychotropic drugs in pregnancy and lactation. Int J Psychiatr Med 1994; 24: 129–49

    Article  CAS  Google Scholar 

  8. Lewis P. Drug usage in pregnancy. In: Lewis P, editor. Clinical pharmacology in obstetrics. Boston (MA): Wright-PSG, 1983

    Google Scholar 

  9. Bennedsen BE, Mortensen PB, Olesen AV, et al. Congenital malformations, stillbirths, and infant deaths among children of women with schizophrenia. Arch Gen Psychiatry 2001; 58: 674–9

    Article  PubMed  CAS  Google Scholar 

  10. Sitland-Marken P, Rickman LA, Wells BG, et al. Management of acute mania in pregnancy. J Clin Psychopharmacol 1989; 9: 78–87

    Article  PubMed  CAS  Google Scholar 

  11. Mortola J. The use of psychotropic agents in pregnancy and lactation. Psychiatr Clin North Am 1989; 12: 69–87

    PubMed  CAS  Google Scholar 

  12. Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153: 592–606

    PubMed  CAS  Google Scholar 

  13. Sobel DE. Fetal damage due to ECT, insulin coma, chlorpromazine or reserpine. Arch Gen Psychiatry 1960; 2: 606–11

    Article  CAS  Google Scholar 

  14. Rieder O, Rosenthal D, Wender P, et al. The off-spring of schizophrenics: fetal and neonatal death. Arch Gen Psychiatry 1975; 32: 200–11

    Article  PubMed  CAS  Google Scholar 

  15. Edlund MJ, Craig TJ. Antipsychotic drug use and birth defects: an epidemiologic reassessment. Compr Psychiatry 1984; 25: 32–8

    Article  PubMed  CAS  Google Scholar 

  16. Ayd FJ. Haloperidol: 15 years of clinical experience. Dis Nerv Syst 1972; 33: 459–69

    PubMed  Google Scholar 

  17. Guze BH, Guze PA. Psychotropic medication use during pregnancy. West J Med 1989; 151: 296–8

    PubMed  CAS  Google Scholar 

  18. Dieulangard P, Coignet J, Vidal JC. Sur un cas d’ectrophocomélie peut-être d’origine médicamenteuse. Bull Féd Gynécol Obstét 1966; 18: 85–7

    Google Scholar 

  19. Kopelman AE, McCullar FW, Heggeness L. Limb malformations following maternal use of haloperidol. JAMA 1975; 231: 62–4

    Article  Google Scholar 

  20. Hanson JW, Oakley Jr GP. Haloperidol and limb deformity [letter]. JAMA 1975; 231: 26

    Article  PubMed  CAS  Google Scholar 

  21. Godet PF, Marie-Cardine M. Neuroleptiques, schizophrenie et grossesse: etude epidemiologique et teratologique. Encephale 1991; 17: 543–7

    PubMed  CAS  Google Scholar 

  22. Lieberman J, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. In: Jones LY, editor. Clozapine in treatment resistant schizophrenia: a scientific update. London: Royal Society of Medicine, 1992

    Google Scholar 

  23. Koren G, Cohn T, Chitayat D, et al. Use of atypical antipsychotics during pregnancy and the risk of neural tube defects in infants. Am J Psychiatry 2002; 159: 136–7

    Article  PubMed  Google Scholar 

  24. Dickson RA, Edwards A. Clozapine and fertility. Am J Psychiatry 1997; 154: 582–3

    PubMed  CAS  Google Scholar 

  25. Tényi T, Trixler M. Clozapine in the treatment of pregnant schizophrenic women. Psychiatria Danubina 1998; 10: 15–8

    Google Scholar 

  26. Dickson RA, Hogg L. Pregnancy of a patient treated with clozapine. Psychiatr Serv 1998; 49: 1081–3

    PubMed  CAS  Google Scholar 

  27. DiMichele V, Ramenghi LA, Sabatino G. Clozapine and lorazepam administration in pregnancy [letter]. Eur Psychiatry 1996; 11: 214

    Article  CAS  Google Scholar 

  28. Stones SC, Sommi Jr RW, Rasken PA, et al. Clozapine use in two full-term pregnancies [letter]. J Clin Psychiatry 1997; 58: 364–5

    Article  Google Scholar 

  29. Tényi T, Trixler M, Vereczkey G, et al. Use of clozapine during pregnancy [in Hungarian]. Orv Hetil 1994; 135: 1967–9

    PubMed  Google Scholar 

  30. Waldman MD, Safferman AZ. Pregnancy and clozapine [letter]. Am J Psychiatry 1993; 150: 168–9

    PubMed  CAS  Google Scholar 

  31. Dev V, Krupp P. The side-effects and safety of clozapine. Rev Contemp Pharmacother 1995; 6: 197–208

    CAS  Google Scholar 

  32. Nguyen HN, Lalonde P. Clozapine et grossesse. Encephale 2003; 29: 119–24

    PubMed  CAS  Google Scholar 

  33. Goldstein DJ, Corbin LA, Fung MC. Olanzapine-exposed pregnancies and lactation: early experience. J Clin Psychopharmacol 2000; 20: 399–403

    Article  PubMed  CAS  Google Scholar 

  34. Lilly Research Laboratories, Lilly Corporate Center. Written correspondence at 2004 Mar 10. Indianapolis (IN): Eli Lilly & Company, 2004. (Data on file)

  35. McDonald AD. Maternal health and congenital defect: a prospective investigation. N Engl J Med 1958; 258: 767–73

    Article  PubMed  CAS  Google Scholar 

  36. Kerly M. Reproductive and perinatal epidemiology. Boca Raton (FL): CRC Press, 1999: 69

    Google Scholar 

  37. Patton SW, Misri S, Corral MR, et al. Antipsychotic medication during pregnancy and lactation in women with schizophrenia: evaluating the risk. Can J Psychiatry 2002; 47: 9559–65

    Google Scholar 

  38. Nagy A, Tényi T, Lénárd K, et al. Olanzapine and pregnancy [in Hungarian]. Orv Hetil 2001; 142: 137–8

    PubMed  CAS  Google Scholar 

  39. Kirchheiner J, Berghofer A, Bolk-Weischedel D. Healthy outcome under olanzapine treatment in a pregnant woman. Pharmacopsychiatry 2000; 33: 78–80

    Article  PubMed  CAS  Google Scholar 

  40. Neumann NU, Frasch K. Olanzapine and pregnancy: 2 case reports [in German]. Nervenarzt 2001; 72: 876–8

    Article  PubMed  CAS  Google Scholar 

  41. Littrell KH, Johnson CG, Peabody CD, et al. Antipsychotics during pregnancy [letter]. Am J Psychiatry 2000; 157: 1342

    Article  PubMed  CAS  Google Scholar 

  42. Ratnayake T, Libretto SE. No complications with risperidone treatment before and throughout pregnancy and during the nursing period. J Clin Psychiatry 2002; 63: 76–7

    Article  PubMed  CAS  Google Scholar 

  43. MacKay FJ, Wilton GL, Pearce SN, et al. The safety of risperidone a post-marketing study on 7684 patients. Hum Psychopharmacol Clin Exp 1998; 13: 413–8

    Article  CAS  Google Scholar 

  44. Tényi T, Trixler M, Keresztes ZS. Quetiapine and pregnancy [letter]. Am J Psychiatry 2002; 159: 674

    Article  PubMed  Google Scholar 

  45. Taylor TM, O’Toole MS, Ohlsen RI, et al. Safety of quetiapine during pregnancy [letter]. Am J Psychiatry 2003; 160: 588–9

    Article  PubMed  Google Scholar 

  46. Food and Drug Administration. Labeling and prescription drug advertising: content and format for labeling for human prescription drugs. Fed Regist 1979; 44: 37434–67

    Google Scholar 

  47. Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry 2002; 63 Suppl. 4: 42–55

    PubMed  CAS  Google Scholar 

  48. Hill RM, Desmond MM, Kay JK. Extrapyramidal dysfunction in an infant of a schizophrenic mother. J Pediatr 1966; 69: 589–95

    Article  PubMed  CAS  Google Scholar 

  49. Tamer A, McKey R, Arias D, et al. Phenothiazine induced extrapyramidal dysfunction in the neonate. J Pediatr 1969; 75: 479–80

    Article  PubMed  CAS  Google Scholar 

  50. Auerbach JG, Hans SL, Marcus J, et al. Maternal psychotropic medication and neonatal behavior. Neurotoxicol Teratol 1992; 14: 399–406

    Article  PubMed  CAS  Google Scholar 

  51. Rayburn WF, Andresen BD. Principles of perinatal pharmacology. In: Rayburn WF, Zuspan FP, editors. Drug therapy in obstetrics and gynecology. Norwalk (CT): Appleton, Century, Crofts, 1982: 1–8

    Google Scholar 

  52. Desmond MM, Rudolph AJ, Hill RM, et al. Behavior alterations in infants born to mothers on psychoactive medication during pregnancy. In: Farrel G, editor. Congenital mental retardation. Austin (TX): University of Texas Press, 1967: 235–44

    Google Scholar 

  53. Hammond JE, Toseland PA. Placental transfer of chlorpromazine. Arch Dis Child 1970; 45: 139–40

    Article  PubMed  CAS  Google Scholar 

  54. L’Hirondel J, Venzia R, Russelot P, et al. Ictere neonatal á la chlorpromazine. Arch Franc Péd 1968; 25: 1171–7

    Google Scholar 

  55. Clark CVH, Gorman D, Vernadakis A. Effects of prenatal administration of psychotropic drugs on behavior of developing rats. Dev Psychobiol 1970; 3: 225–35

    Article  PubMed  CAS  Google Scholar 

  56. Golub M, Kornetsky C. Seizure susceptibility and avoidance conditioning in adult rats treated prenatally with chlorpromazine. Dev Psychobiol 1974; 7: 79–88

    Article  PubMed  CAS  Google Scholar 

  57. Spear IP, Shalaby IA, Brick J. Chronic administration of haloperidol during development: behavioral and psychopharmacological effects. Psychopharmacology (Berl) 1980; 70: 47–58

    Article  CAS  Google Scholar 

  58. Kris EB. Children of mothers maintained on pharmacotherapy during pregnancy and postpartum. Curr Ther Res 1965; 7: 785–9

    PubMed  CAS  Google Scholar 

  59. Stika L, Elisova K, Honzakova L, et al. Effects of drug administration in pregnancy on children’s school behaviour. Pharm Weekbl Sci 1990; 12: 252–5

    Article  PubMed  CAS  Google Scholar 

  60. Pearson KH, Nonacs R, Cohen LS. Practical guidelines for the treatment of psychiatric disorders during pregnancy. In: Pearson KH, Sonawalla SB, Rosenbaum JF, editors. Women’s health and psychiatry. Philadelphia (PA): Lippincott Williams &Wilkins, 2002: 115–25

    Google Scholar 

  61. Viguera AC, Baldessarini RJ, Hegarty JD, et al. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997; 54: 49–55

    Article  PubMed  CAS  Google Scholar 

  62. Dencker SJ, Malm U, Lepp M. Schizophrenic relapse after drug withdrawal is predictable. Acta Psychiatr Scand 1986; 73: 181–5

    Article  PubMed  CAS  Google Scholar 

  63. Carpenter Jr WT, Hanlon TE, Heinrichs DW, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990; 147: 1138–48

    PubMed  Google Scholar 

  64. Baldessarini RJ, Viguera AC. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995; 52: 189–92

    Article  PubMed  CAS  Google Scholar 

  65. Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 1995; 52: 173–88

    Article  PubMed  CAS  Google Scholar 

  66. Casiano ME, Hawkins DR. Major mental illness and childbearing: a role for the consultation-liaison psychiatrist in obstetrics. Psychiatr Clin North Am 1987; 10: 37–51

    Google Scholar 

  67. Miller LJ. Clinical strategies for the use of psychotropic drugs during pregnancy. Psychiatry Med 1991; 9: 275–98

    CAS  Google Scholar 

  68. Bernstein JG. Psychotropic drugs in pregnancy and lactation. In: Bernstein JG, editor. Handbook of drug therapy in psychiatry. 3rd ed. St Louis (MO): Mosby-Year Book Inc., 1995: 397–412

    Google Scholar 

  69. Trixler M, Tényi T. Antipsychotic use in pregnancy: what are the best treatment options? Drug Saf 1997; 16: 403–10

    Article  PubMed  CAS  Google Scholar 

  70. Wadhwa PD, Sandman CA, Garite TJ. The neurobiology of stress in human pregnancy: implications for prematurity and development of the fetal central nervous system. In: Russell JA, Douglas AJ, Windle RJ, et al., editors. The maternal brain: neurobiological and neuroendocrine adaptation and disorders in pregnancy and post partum. Amsterdam: Elsevier, 2001: 131–42

    Google Scholar 

  71. Zuckerman B, Amaro H, Bauchner H, et al. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol 1989; 160: 1107–11

    PubMed  CAS  Google Scholar 

  72. Weinberg M, Tronick E. The impact of maternal psychiatric illness on infant development. J Clin Psychiatry 1998; 59: 63–71

    Google Scholar 

  73. Codero JF, Oakley GP. Drug exposure during pregnancy: some epidemiologic considerations. Clin Obstet Gynecol 1983; 26: 418–28

    Article  Google Scholar 

  74. Stowe ZN, Nemeroff CB. Psychopharmacology during pregnancy and lactation. In: Schatzberg AF, Nemeroff CB, editors. Textbook of psychopharmacology. Washington, DC: American Psychiatric Press, 1998: 979–96

    Google Scholar 

  75. Spielvogel A, Wile J. Treatment and outcomes of psychotic patients during pregnancy and childbirth. Birth 1992; 19: 131–7

    Article  PubMed  CAS  Google Scholar 

  76. Hendrick V, Altshuler L, Cohen L, et al. Evaluation of mental health and depression during pregnancy: position paper. Psychopharmacol Bull 1998; 34: 297–9

    PubMed  CAS  Google Scholar 

  77. Cohen LS. Psychotropic drug use in pregnancy. Hosp Community Psychiatry 1989; 40: 566–7

    PubMed  CAS  Google Scholar 

  78. Werler MM, Louik C, Shapiro S, et al. Pre-pregnancy weight in relation to risk of neural tube defects. JAMA 1996; 275: 1089–92

    Article  PubMed  CAS  Google Scholar 

  79. Shaw GM, Velie EM, Schaffer D. Risk of neural tube defectaffected pregnancies among obese women. JAMA 1996; 275: 1093–6

    Article  PubMed  CAS  Google Scholar 

  80. Llewellyn A, Stove ZN, Strader Jr JR. The use of lithium and management of women with bipolar disorder during pregnancy and lactation. J Clin Psychiatry 1998; 59 Suppl. 6: 57–64

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Psychiatry, University Medical School of Pécs, Rét u. 2, Pécs, H-7623, Hungary

    Mátyás Trixler, Ágnes Gáti, Sándor Fekete & Tamás Tényi

Authors
  1. Mátyás Trixler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ágnes Gáti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sándor Fekete
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tamás Tényi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mátyás Trixler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trixler, M., Gáti, Á., Fekete, S. et al. Use of Antipsychotics in the Management of Schizophrenia during Pregnancy. Drugs 65, 1193–1206 (2005). https://doi.org/10.2165/00003495-200565090-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200565090-00002

Keywords

Search

Navigation